Showing results (21-30 of 374) with videos related to
Sort By:
Pageof 38
European Journal of Clinical Investigation|November 3, 2010
The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular diseaseJan Westerink, Yolanda van der Graaf, Daniël R Faber, et al.BMC Cardiovascular Disorders|July 7, 2011
Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort studySharmini Selvarajah, Yolanda van der Graaf, Frank L J Visseren, et al.European Journal of Internal Medicine|June 19, 2007
Defining the metabolic syndrome: Resolving unresolved issues?Jobien K Olijhoek, Yolanda van der Graaf, Steven M Haffner, et al.Journal of Vascular Surgery|April 29, 2008
Intra-abdominal fat and metabolic syndrome are associated with larger infrarenal aortic diameters in patients with clinically evident arterial diseasePetra M Gorter, Frank L J Visseren, Frans L Moll, et al.Obesity (Silver Spring, Md.)|April 21, 2012
The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseasesJoris W P Vernooij, Yolanda van der Graaf, Frank L J Visseren, et al.Obesity (Silver Spring, Md.)|June 15, 2007
Abdominal fat and risk of coronary heart disease in patients with peripheral arterial diseaseBeate G Brouwer, Frank L J Visseren, Ronald P Stolk, et al.Journal of Hypertension|October 9, 2012
Relation between adiposity and hypertension persists after onset of clinically manifest arterial diseaseJohannes A N Dorresteijn, Wilko Spiering, Yolanda Van Der Graaf, et al.European Journal of Cardiovascular Nursing|August 3, 2010
The effect of self-efficacy on cardiovascular lifestyleBerna G M Sol, Yolanda van der Graaf, Rutger van Petersen, et al.European Journal of Preventive Cardiology|July 5, 2011
Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseasesJan Westerink, Yolanda van der Graaf, Daniël R Faber, et al.Gynecologic Oncology|January 30, 2009
Is centralization of ovarian cancer care warranted? A cost-effectiveness analysisJacoba P Greving, Flora Vernooij, A Peter M Heintz, et al.Pageof 38